Reason for request

Inclusion for hospital use in the extension of indication: "Conditioning before HSC (Haemopoietic Stem Cell) transplantation. -Prevention of graft versus host disease after allogenic HSC transplant. This medicinal product is indicated for use particularly in stem cell transplantation from unrelated volunteer donors in combination with standard treatments for malignant haematological disorders.”

-


Clinical Benefit

Substantial

The actual benefit of the proprietary medicinal product is substantial.


Clinical Added Value

no clinical added value

In the absence of a comparison with THYMOGLOBULIN, a rabbit anti-thymocyte immunoglobulin and the comparison medicinal product, ANTILYMPHOCYTE GLOBULINS FRESENIUS does not offer an improvement in actual benefit (IAB V) when used for conditioning for haemopoietic stem cell transplantation or to prevent graft versus host disease after allogenic haemopoietic stem cell transplantation.


Contact Us

Évaluation des médicaments

See also